{"filings":[{"id":1498676,"accession_number":"0001193125-26-297454","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2026-07-07T20:04:11+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vor BioPharma appoints David Zaccardelli to board; director Andrew Levin resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Levin resigned as director effective July 6, 2026; no disagreement with the company.","David Zaccardelli appointed as independent Class II director, term until 2029 annual meeting.","Zaccardelli is former CEO of Verona Pharma (acquired by Merck 2025), Dova, and Cempra.","He receives standard non-employee director compensation: $40k annual cash retainer, initial option grant of up to 68k shares or $700k.","No material transactions or arrangements exist between Zaccardelli and the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027477,"accession_number":"0001193125-26-269431","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2026-06-12T20:11:14+00:00","items":["5.07","9.01"],"status":"ready","headline":"Vor Bio stockholders approve amended 2021 equity plan and elect two Class II directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Andrew Levin, M.D., Ph.D. elected with 25,797,081 for, 120,813 withheld; Fouad Namouni, M.D. elected with 22,825,938 for, 4,091,956 withheld.","Amended 2021 Equity Incentive Plan approved (20,146,430 for, 6,767,428 against, 4,036 abstain).","Plan amendment expands evergreen provision to include pre-funded warrants in share reserve calculation and adds automatic full vesting of time-based awards upon employee death.","Ratification of Ernst & Young as independent auditor for FY 2026 passed (33,877,004 for, 133,499 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":917961,"accession_number":"0001193125-26-261661","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2026-06-08T20:01:29+00:00","items":["7.01","9.01"],"status":"ready","headline":"RemeGen gets NMPA nods for telitacicept in IgAN and Sjögren’s; Vor Bio holds ex-China rights","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["First BAFF/APRIL-targeting therapy approved for IgA nephropathy; conditional NMPA approval based on Phase 3 TELIGAN trial showing 55% placebo-adjusted UPCR reduction.","First regulatory approval ever for Sjögren’s disease in China; Phase 3 met primary and secondary endpoints (ESSDAI, ESSPRI).","Telitacicept now has five approved indications in China; Vor Bio holds exclusive development/commercialization rights outside Greater China.","Phase 3 IgAN results recently published in NEJM; eGFR stable at 39 weeks vs declines on placebo.","Vor Bio CEO cites milestone validating dual BAFF/APRIL inhibition as potential foundational therapy for autoimmune diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108996,"accession_number":"0001193125-26-127609","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Vor Biopharma raises $75M via private placement with TCGX for telitacicept development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $75M from sale of 5.34M shares at $14.05/share to TCGX affiliates.","Closing expected March 30, 2026; no placement agent used.","Proceeds to advance Phase 3 trials for myasthenia gravis and primary Sjögren's disease.","TCGX managing partner expresses confidence in telitacicept's differentiated profile.","Registration rights agreement to file resale registration statement within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108995,"accession_number":"0001193125-26-009961","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vor Biopharma reports preliminary cash of ~$450M as of Dec 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Cash, cash equivalents and short-term investments ~$450M as of Dec 31, 2025 (preliminary, unaudited).","Company presenting at 44th Annual J.P. Morgan Healthcare Conference on Jan 13, 2026.","Financial data is subject to change upon completion of audited FY 2025 statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108994,"accession_number":"0001193125-26-000905","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vor Biopharma Chief Development Officer Qing Zuraw departs Dec 31; gets $565K severance + consulting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Qing Zuraw, Chief Development Officer, resigned effective Dec 31, 2025 to pursue other opportunities.","Separation pay of $565,000 (12 months) plus $115,724 prorated 2025 target bonus; retains $100K signing bonus.","All unvested stock options and RSUs forfeited (no vesting before one-year anniversary).","Company expects to enter a consulting arrangement with Zuraw for Q1 2026 to assist transition.","Separation includes 12-month non-compete, non-disparagement, and standard confidentiality covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125456,"accession_number":"0001193125-25-324768","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Vor Bio raises $150M in private placement; appoints two new directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 13.9M shares at $10.81 for gross proceeds of ~$150M.","New/existing investors include RA Capital, Forbion, Frazier Life Sciences, Caligan, Logos, Venrock.","Proceeds to advance telitacicept Phase 3 trials for myasthenia gravis and Sjögren's disease.","Director Sarah Reed resigned; Andrew Levin (RA Capital) and Wouter Joustra (Forbion) appointed.","Levin and Joustra receive standard director fees and option grants of 3,000 shares each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125455,"accession_number":"0001193125-25-311957","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vor Biopharma reprices employee stock options to $8.18; CEO gets 4.16M options repriced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board reduced exercise price of ~5.2M underwater options to $8.18, the Dec 5, 2025 closing price.","Repriced options originally ranged from $17.80 to $47.60; CEO Jean-Paul Kress repriced 4,164,831 options.","Retention period ends Dec 5, 2027; options exercised earlier retain original exercise price.","CFO Sandy Mahatme received option for 1,388,274 shares at $17.80, reducing to $8.18 after retention period.","Repricing aims to retain employees and avoid dilution from new equity grants or cash comp."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125454,"accession_number":"0001193125-25-275862","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vor Biopharma announces $100M public offering of 10M shares at $10 each to fund telitacicept development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["10,000,000 shares at $10.00 each; expected net proceeds ~$93.7M (or $107.8M if underwriters' option fully exercised).","Proceeds to advance telitacicept clinical development including Phase 3 trial for primary Sjögren's Disease, plus manufacturing/pre-commercialization.","Offering expected to close November 12, 2025; underwriters have 30-day option for up to 1,500,000 additional shares.","As of Sept 30, 2025, outstanding shares were 9,026,922; offering represents ~111% dilution if fully exercised.","Company believes current cash plus proceeds will fund operations into Q2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125453,"accession_number":"0001193125-25-261723","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vor Bio appoints Jeremy Sokolove CMO; amends CDO severance terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jeremy Sokolove appointed CMO effective Nov 3, 2025; has >20 yrs rheumatology/autoimmune R&D experience.","Sokolove previously CMO-in-Residence at Roivant Sciences, SVP at GSK, Head of Immunology at AbbVie.","Vor Bio emphasizes Telitacicept (dual BAFF/APRIL inhibitor) as near-term opportunity for autoimmune patients.","Amended CDO Dr. Qing Zuraw's severance: pro-rated 2025/2026 target bonus if terminated w/o cause, or if resigns after Dec 31, 2025.","Employment amendment effective for five months from Nov 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125452,"accession_number":"0001193125-25-253636","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vor Biopharma reports 48-week Phase 3 data for telitacicept in Sjögren's disease from China","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Webcast held Oct 28, 2025 to discuss late-breaking 48-week Phase 3 results from China.","Trial evaluates telitacicept in primary Sjögren's disease; no specific efficacy/safety numbers provided in the filing text.","Stock may react to implied data direction, but actual results are not disclosed in this 8-K excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142190,"accession_number":"0001193125-25-205553","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["3.03","8.01","9.01"],"status":"ready","headline":"Vor Biopharma announces 1-for-20 reverse stock split effective Sept 18, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split at 1-for-20 ratio effective 5:00 p.m. ET on September 18, 2025.","Pre-split shares ~136.8M; post-split ~6.84M (subject to fractional share cash-out).","Split-adjusted trading on Nasdaq begins September 19, 2025; new CUSIP 929033207.","Proportionate adjustments to exercise prices and shares under equity plans and warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142189,"accession_number":"0001193125-25-193600","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vor Biopharma files corporate presentation; no material new disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing furnishes a September 2025 corporate presentation under Item 7.01.","Presentation available on company website; no specific financial or operational updates provided.","No earnings, guidance, or material events announced in the filing or exhibit.","Presentation title: 'Global Science. One Purpose.' — no quantified data included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142188,"accession_number":"0001193125-25-189435","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vor Biopharma announces three director resignations, appoints Sarah Reed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joshua Resnick, Matthew Patterson, and David Lubner resigned from the Board effective Aug 25-26, 2025; no disagreement cited.","Sarah Reed, General Counsel of RA Capital Management, appointed as independent Class II director effective Aug 27.","Reed receives standard compensation: $40k cash retainer, option to purchase 60k shares, and annual option grants.","Appointment was per securities purchase agreement with RA Capital, which holds >5% of VOR voting stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142187,"accession_number":"0001193125-25-189169","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Vor Biopharma stockholders approve reverse stock split, equity plan amendment; files $119.7M ATM prospectus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split in range 1-for-5 to 1-for-30; board to determine ratio.","Approved amendment to 2021 equity plan to add 25M shares and reduce annual evergreen from 5% to 4%.","Approved issuance of common stock underlying outstanding warrants for Nasdaq Listing Rule 5635(d) compliance.","Filed prospectus supplement to register up to $119.7M of common stock for ATM offering through Stifel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142186,"accession_number":"0001193125-25-162644","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vor Bio appoints Qing Zuraw as CDO, Michel Detheux and Bo Cumbo as directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignation of director Sven (Bill) Ante Lundberg effective July 17, 2025; no disagreement cited.","Qing Zuraw appointed CDO; over 25 years in autoimmune diseases; previously led telitacicept trials at RemeGen.","Zuraw's compensation: $565k base salary, 40% target bonus, $200k signing bonus, 4.37M options, 937k RSUs.","Board expanded to 10; Michel Detheux (CEO iTeos) and Alexander Cumbo (CEO Solid Biosciences) as independent directors.","New directors receive $40k cash retainer, initial 60k options, annual 30k options per standard policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142185,"accession_number":"0001193125-25-157638","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vor Biopharma appoints Sandesh Mahatme as CFO and Chief Business Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandesh Mahatme appointed CFO, Principal Financial Officer and Principal Accounting Officer, effective July 9, 2025.","Mahatme previously served as President, COO and CFO of National Resilience Inc., raising over $2.5B in capital.","His initial base salary is $480,000, with a 40% target bonus and a $274,000 signing bonus.","Received a grant of 13,882,750 RSUs under the 2023 Inducement Plan; severance includes 12–18 months base salary.","Mahatme also joins as Chief Business Officer, bringing experience from Sarepta and Celgene."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160188,"accession_number":"0001193125-25-147339","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","1.02","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Vor Bio licenses telitacicept from RemeGen for $125M upfront, raises $175M PIPE, appoints new CEO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License deal: Vor Bio gets ex-China rights to telitacicept (global Phase 3 for gMG) for $125M upfront ($45M cash + $80M warrants); up to $4B+ milestones plus royalties.","Private Placement: $175M gross from pre-funded warrants to buy 700M shares at $0.25/warrant; closing expected June 27, 2025.","CEO change: Robert Ang resigned; Jean-Paul Kress (ex-MorphoSys CEO) appointed CEO and Chairman. Dr. Ang stays as advisor through October.","Cambridge lease terminated: $8.5M termination fee paid; $2.4M letter of credit to be returned. Lease was set to expire in 2030.","Stockholders representing ~63% voting power signed support agreements to approve share issuance and charter amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160187,"accession_number":"0001193125-25-125833","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Vor Biopharma shareholders OK share increase to 800M, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 400M to 800M; approved by 65.5M votes for vs 7.7M against.","Class I directors Matthew Patterson and Daniella Beckman re-elected with ~53.4M and ~52.7M votes for.","Ernst & Young LLP ratified as independent auditor for FY2025 with 73.1M votes for.","Annual meeting had 73.2M shares represented, ~58.7% of outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160186,"accession_number":"0001193125-25-123141","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vor Biopharma CEO Robert Ang designated Principal Financial Officer and Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board designated CEO Robert Ang as principal financial and accounting officer effective May 19, 2025.","No new compensation arrangements were entered into or amended in connection with the designation.","Dr. Ang continues as President, CEO, and director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160185,"accession_number":"0001193125-25-115554","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.05","5.02","8.01","9.01"],"status":"ready","headline":"Vor Bio winds down operations, cuts 95% of staff, and explores sale or merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved wind-down of clinical and manufacturing operations; workforce reduced by 147 employees (~95%).","Total wind-down cost estimated at $19.3M including $10.9M in severance and $4.4M asset write-down.","CFO Han Choi and CSO Tirtha Chakraborty terminated without cause effective May 16, 2025; severance of ten months salary.","Company exploring strategic alternatives including asset sale, licensing, merger, or sale of the company.","Cash, cash equivalents and marketable securities were $91.9M as of Dec 31, 2024; Q1 results due May 14."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160184,"accession_number":"0001193125-25-096692","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vor Biopharma receives Nasdaq notice for non-compliance with $1.00 minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received April 22, 2025; stock below $1.00 for 30 consecutive business days.","Company has 180 calendar days (until Oct 20, 2025) to regain compliance.","To cure, bid price must close at $1.00+ for 10 consecutive business days.","May transfer to Nasdaq Capital Market for an additional 180-day grace period if needed.","If not cured, stock faces potential delisting; company is evaluating options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160183,"accession_number":"0001193125-25-072340","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chief Medical Officer Eyal Attar resigns effective April 18, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eyal C. Attar, M.D., resigned as Chief Medical Officer of Vor Biopharma, effective April 18, 2025.","Resignation is to pursue a new opportunity; no successor named yet.","Company expects to enter into a consulting agreement for transition services.","Dr. Attar's departure may impact ongoing clinical development activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178495,"accession_number":"0001193125-25-021763","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vor Biopharma reprices 6.76M underwater stock options to $1.34 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board reduces exercise price to $1.34 for options with original prices from $1.36 to $44.96.","Repricing applies to continuing employees; CEO's 2.13M options repriced (avg $4.30).","Options may not be exercised at reduced price before February 3, 2026 retention end.","CSO Tirtha Chakraborty and CMO Eyal Attar also have options repriced.","Move intended to retain and motivate employees without additional equity or cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178494,"accession_number":"0001193125-25-003259","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vor Bio appoints Erez Kalir to board, filling new seat linked to Reid Hoffman-led PIPE","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 8 members; Kalir designated by Reprogrammed Interchange (Hoffman entity).","Kalir is co-founder & COO of Manas AI, managing member of Martial Eagle Fund, venture partner at FJ Labs.","Standard director compensation: $40k cash retainer + option for 60k shares, plus annual 30k-share options.","Appointment follows a December 2024 PIPE led by Reid Hoffman; Kalir serves as Class III director until 2027.","Kalir's background includes Tiger Management, Sabretooth Capital, and a Rhodes Scholarship."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195165,"accession_number":"0001193125-24-285627","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Vor Bio raises $55.6M in PIPE; extends cash runway to 2025 clinical data readouts","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 55.87M shares and warrants for 69.84M shares at combined $0.99425 price, gross proceeds ~$55.6M.","New investor Reid Hoffman led; existing investor RA Capital participated; each gets one board seat and one observer seat.","Updated Phase 1/2 VCAR33 ALLO data expected H1 2025; Phase 1/2a trem-cel+Mylotarg data H2 2025.","Net proceeds to fund pipeline development and general corporate; warrant exercise could add $58.5M.","Warrants exercisable at $0.838/share, expire 7 years from issuance; closing expected Dec 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195164,"accession_number":"0001193125-24-272891","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vor Bio announces positive clinical data for trem-cel + Mylotarg in AML; FDA agrees on registrational trial design","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Preliminary data shows median RFS not reached after 7.4 months follow-up in 15 AML patients treated with trem-cel + Mylotarg.","Engraftment achieved in 100% of patients: neutrophil engraftment median 9.5 days, platelet recovery median 16 days.","CD33 editing efficiency median 90% (range 71-94%); doses up to 2 mg/m2 without significant toxicity.","FDA agreed on registrational trial design for trem-cel + Mylotarg, including study population, control arm, primary endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211434,"accession_number":"0001193125-24-228399","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vor Bio appoints Han Choi as CFO, effective Sept 30, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Han Choi, M.D., LL.M., named CFO; previously Principal at Oracle Investment Management for over 20 years.","Base salary of $464,000 per year and target annual bonus of 40% of base salary.","Granted stock option for 400,000 shares, vesting over 4 years (1/4 after 1 year, then monthly).","Choi brings experience in healthcare investment, business development, and capital markets strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211433,"accession_number":"0001193125-24-214186","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vor Bio reports positive trem-cel + Mylotarg data; plans pivotal trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/2 VBP101: 18 patients received trem-cel; 10 received Mylotarg as of July 19, 2024 cut-off.","100% engraftment (median 9 days); CD33 editing efficiency median 89%; full myeloid chimerism at Day 28.","Shielding maintained neutrophil/platelet counts across Mylotarg doses 0.5, 1, 2 mg/m^2.","Early relapse-free survival benefit vs high-risk AML comparators; only 4 relapses recorded.","New preclinical ADC VADC45 targeting CD45; IND-enabling studies planned; FDA pivotal trial discussion by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211432,"accession_number":"0001193125-24-211050","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vor Biopharma receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Vor Biopharma on Aug 29, 2024 that its common stock bid price has been below $1.00 for 30 consecutive business days.","Company has until Feb 25, 2025 to regain compliance by closing at or above $1.00 for at least 10 consecutive business days.","If not compliant by Feb 2025, Vor may transfer to Nasdaq Capital Market for an additional 180-day grace period, subject to other listing requirements.","Delisting risk exists if compliance not regained or transfer not completed; company monitoring options including potential reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230073,"accession_number":"0001193125-24-158320","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vor Biopharma CFO Nathan Jorgensen resigns; CEO Ang named interim principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nathan Jorgensen resigns as CFO effective June 21, 2024, to pursue a new opportunity; no disagreement cited.","CEO Robert Ang appointed interim principal financial officer; VP of Finance Amy Quinlan interim principal accounting officer.","Company has launched search for a permanent CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230072,"accession_number":"0001193125-24-148151","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Vor Biopharma shareholders approve equity plan amendment to 5% annual share increase, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amended 2021 Equity Incentive Plan raising automatic annual share increase from 4% to 5% through 2034.","Robert Ang and Sven (Bill) Ante Lundberg were elected as Class III directors until the 2027 annual meeting.","Ernst & Young ratified as independent auditor for fiscal year 2024.","Plan amendment received 36.8M votes for, 20.9M against; 4.4M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230071,"accession_number":"0001193125-24-129357","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vor Bio appoints Blueprint R&D President Fouad Namouni to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed independent Class II director effective April 30, 2024; term until 2026 annual meeting.","Dr. Namouni has over 20 years oncology drug development; currently President of R&D at Blueprint Medicines.","Receives standard non-employee director compensation: $40,000 cash retainer plus 60,000 stock option.","Company highlights his experience in cell/genome engineering for acute myeloid leukemia pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248507,"accession_number":"0001193125-24-003459","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vor Biopharma updates investor presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an updated corporate presentation under Item 8.01 on January 5, 2024.","Presentation reiterates ambition to cure blood cancers via cell and genome engineering.","No financial results, guidance, clinical data, or strategic updates were provided.","Exhibit 99.1 includes only a title slide; full content was not disclosed in the filing.","The update appears routine with no new business developments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266010,"accession_number":"0001193125-23-268939","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vor Bio: ASH presentations show trem-cel engraftment; CD33CART 40% complete remission at highest dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VBP101 (trem-cel) abstract accepted for oral at ASH; shows robust neutrophil engraftment and hematologic protection from Mylotarg.","CD33CART Phase 1: 2/5 (40%) evaluable patients at DL4 achieved complete remission; 4/19 had CRS ≥ Grade 3.","VCAR33 ALLO uses same CAR-T construct as CD33CART but from healthy donors; VBP301 trial-in-progress poster at ASH.","Preclinical collaboration with Janssen: CD33-deleted allografts synergistic with JNJ-67571244, reducing cytokines.","Single-cell analysis of 28 AML patients (most comprehensive to date) accepted for oral presentation at ASH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302658,"accession_number":"0001193125-23-163990","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vor Bio reports engraftment data from 5 AML patients in trem-cel study; FDA clears VCAR33 ALLO IND","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 5 trem-cel patients achieved neutrophil engraftment in 10-11 days; high myeloid donor chimerism at day 28.","Patient 2 had secondary graft failure coincident with coronavirus hKU1 and antimicrobials; backup graft restored engraftment.","Patient 3 has recovering platelets with autoimmune thrombocytopenia; count 15,000/µL independent of transfusions.","Patients 4 and 5 had normal engraftment and recovery with no unexpected adverse events; cell doses met release criteria.","FDA cleared IND for VCAR33 ALLO (allogeneic CAR-T targeting CD33); VBP301 trial to focus on relapsed post-allo-SCT patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302657,"accession_number":"0001193125-23-155416","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vor Biopharma stockholders elect Lubner and Resnick as Class II directors, ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David C. Lubner elected with 53,754,258 votes for, 45,048 withheld (4,500,866 broker non-votes).","Joshua Resnick, M.D. elected with 44,270,251 votes for, 9,529,055 withheld (4,500,866 broker non-votes).","Ratification of Ernst & Young as independent auditor for FY2023 approved: 58,294,758 for, 1,908 against, 3,506 abstentions.","Approximately 87% of outstanding shares (58.3M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302656,"accession_number":"0001193125-23-102020","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Kush Parmar resigns from Vor Biopharma board before 2023 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kush Parmar, M.D., Ph.D., resigned effective immediately prior to the 2023 Annual Meeting.","Parmar was one of the longest-tenured directors, joining the Board in February 2019.","He previously served as Board chair (Jan-Jun 2021) and interim CEO (Feb-Aug 2019).","The resignation was not due to any disagreement with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322305,"accession_number":"0001193125-23-040919","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vor Bio announces additional Phase 1/2a data: trem-cel protects against Mylotarg hematotoxicity in AML patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First AML patient maintained neutrophil and platelet counts ~5 months post trem-cel transplant through three Mylotarg doses at 0.5 mg/m².","No Mylotarg-related hematotoxicity observed; only low-grade nausea/vomiting reported as possibly related.","Second patient engrafted normally with neutrophil recovery Day 11, platelet recovery Day 17; no unexpected AEs in both patients.","CD33-negative donor hematopoiesis enriched across cell types after Mylotarg, suggesting potential for combo therapy.","Company on track to file IND in H1 2023 for VCAR33 ALLO allogeneic CAR-T to combine with trem-cel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340348,"accession_number":"0001193125-22-311777","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Vor Biopharma enters into $125M at-the-market equity sales agreement with Stifel","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Stifel for up to $125M of common stock sales in at-the-market offerings.","Stifel will receive a commission of 3.0% of gross sales proceeds from shares sold.","Replaces prior ATM agreement with Jefferies LLC, which was terminated on Dec 22, 2022.","Company has no obligation to sell shares; sales are at its sole discretion.","Prospectus supplement filed under existing Form S-3 registration statement (333-263541)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340347,"accession_number":"0001193125-22-304849","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Vor Biopharma terminates at-the-market sales agreement with Jefferies LLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notice of termination given December 9, 2022; effective December 22, 2022.","Sales agreement allowed at-the-market offerings of common stock through Jefferies.","Through termination, 856,030 shares sold for net proceeds of $4.3 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340346,"accession_number":"0001193125-22-300211","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Vor Biopharma prices $115.8M combined stock offering and private placement at $4.30/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["15.3M shares sold in underwritten offering for gross $65.8M; 11.6M shares in private placement to RA Capital for $50M.","Net proceeds from underwritten offering estimated at $61.4M after discounts and expenses; private placement net not disclosed.","Proceeds to fund clinical pipeline development and working capital; closings expected December 9, 2022.","Private placement shares are unregistered; company must file resale registration by Jan 8, 2023 or issue warrants by Dec 31, 2022.","Underwriters: Evercore, Stifel, Oppenheimer; RA Capital is company's largest stockholder."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340345,"accession_number":"0001193125-22-299797","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vor Bio reports initial clinical proof-of-concept for trem-cel; first AML patient engrafts normally","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient received trem-cel dose of 7.6x10^6 CD34+ cells/kg with 88% CD33 editing efficiency.","Neutrophil engraftment at 10 days, platelet recovery Day 22; >90% of PBMCs CD33-negative, 100% donor chimerism.","No infusion reactions or treatment-related adverse events observed post-transplant.","Mylotarg 0.5 mg/m^2 tolerated with no neutropenia or liver enzyme changes through Day 20.","Trial continues enrolling; additional data expected in 2023; conference call Dec 7 at 8am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340344,"accession_number":"0001193125-22-294013","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2022-11-29T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Vor Biopharma confirms VOR33 engraftment and hematological protection data to be announced later this year","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Vor Biopharma presented at Piper Sandler 34th Annual Healthcare Conference on November 29, 2022.","Company confirmed upcoming VOR33 data will include engraftment data and hematological protection data.","Data follows treatment with Mylotarg in at least one patient.","VOR33 data expected to be announced later this year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376210,"accession_number":"0001193125-22-176471","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vor Biopharma stockholders elect three Class I directors and ratify E&Y as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Matthew Patterson, Daniella Beckman, and Kush Parmar as Class I directors for terms until 2025.","Ratification of Ernst & Young LLP as independent auditor for FY2022: 28,763,851 votes for, 3,220 against, 2,428 abstain.","Approximately 76.69% of eligible shares were represented at the Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376209,"accession_number":"0000950170-22-005694","cik":1817229,"company_name":"Vor Biopharma Inc.","ticker":"VOR","form_type":"8-K","filed_at":"2022-04-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vor Biopharma CMO Christopher Slapak to retire effective May 6, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Christopher Slapak, Chief Medical Officer, will terminate employment on May 6, 2022 due to retirement.","Severance benefits consistent with the Company's Executive Severance and Change in Control Benefits Plan.","Separation agreement to be filed as an exhibit to Q2 2022 Form 10-Q.","No successor appointed as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":765650000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}